Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 7, 2010, Pages 1441-1447

  Haas, Wolfgang ^a   Pillar, Chris M ^b   Hesje, Christine K ^a   Sanfilippo, Christine M ^a   Morris, Timothy W ^a  

^a BAUSCH AND LOMB   (United States)

^b Eurofins Medinet Inc   (Germany)

Author keywords

Bactericidal activity; Fluoroquinolones; Time kill

Indexed keywords

ANTIINFECTIVE AGENT; AZITHROMYCIN; BESIFLOXACIN; CIPROFLOXACIN; GATIFLOXACIN; MOXIFLOXACIN; TOBRAMYCIN; UNCLASSIFIED DRUG; 7-(3-AMINOHEXAHYDRO-1H-AZEPIN-1-YL)-8-CHLORO-1-CYCLOPROPYL-6-FLUORO-1,4-DIHYDRO-4-OXO-3-QUINOLINECARBOXYLIC ACID; AMINOGLYCOSIDE; AZEPINE DERIVATIVE; BACTERIAL DNA; BETA LACTAM; MACROLIDE; QUINOLONE DERIVATIVE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG POTENCY; HAEMOPHILUS INFLUENZAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS PNEUMONIAE; BACTERIAL GENE; CHEMISTRY; COMPARATIVE STUDY; CONJUNCTIVITIS; DNA SEQUENCE; DRUG EFFECTS; GENETICS; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; MICROBIOLOGY; TIME;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; AZEPINES; BETA-LACTAMS; CONJUNCTIVITIS; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; GENES, BACTERIAL; HAEMOPHILUS INFLUENZAE; HUMANS; MACROLIDES; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; SEQUENCE ANALYSIS, DNA; STAPHYLOCOCCUS; STREPTOCOCCUS PNEUMONIAE; TIME FACTORS;

EID: 77954188913     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq127     Document Type: Article

References (27)

1. Wolfson JS, Hooper DC, Swartz MN. Mechanisms of action and resistance to quinolone antimicrobial agents. In: Wolfson JS, Hooper DC, eds. Quinolone Antimicrobial Agents. Washington, DC: ASM Press, 1989; 5-34.
2. Haas W, Pillar CP, Zurenko GE et al. Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. Antimicrob Agents Chemother 2009; 53: 3552-60.
3. Clinical and Laboratory Standards Institute. Methods for Determining Bactericidal Activity of Antimicrobial Agents: Approved Guideline M26-A. CLSI, Wayne, PA, USA, 1999.
4. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Approved Standard M7-A7. CLSI, Wayne, PA, USA, 2006.
5. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Eighteenth Informational Supplement M100-S18. Wayne, PA, USA: CLSI, 2008.
6. Schwalbe R, Steele-Moore L, Goodwin AC. Antimicrobial Susceptibility Testing Protocols. New York: CRC Press, 2007.
7. Ferrara A, Dos SC, Cimbro M et al. Comparative antimicrobial activity and post-antibiotic effect of azithromycin, clarithromycin and roxithromycin against some respiratory pathogens. Int J Antimicrob Agents 1996; 7: 181-6.
8. Retsema J, Girard A, Schelkly W et al. Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. Antimicrob Agents Chemother 1987; 31: 1939-47.
9. Ince D, Zhang X, Hooper DC. Activity of and resistance to moxifloxacin in Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47: 1410-5.
10. Ba BB, Arpin C, Vidaillac C et al. Activity of gatifloxacin in an in vitro pharmacokinetic-pharmacodynamic model against Staphylococcus aureus strains either susceptible to ciprofloxacin or exhibiting various levels and mechanisms of ciprofloxacin resistance. Antimicrob Agents Chemother 2006; 50: 1931-6.
11. Davies TA, Kelly LM, Hoellman DB et al. Activities and postantibiotic effects of gemifloxacin compared to those of 11 other agents against Haemophilus influenzae and Moraxella catarrhalis. Antimicrob Agents Chemother 2000; 44: 633-9.
12. Horii T, Suzuki Y, Monji A et al. Detection of mutations in quinolone resistance-determining regions in levofloxacin and methicillin-resistant Staphylococcus aureus: effects of the mutations on fluoroquinolone MICs. Diagn Microbiol Infect Dis 2003; 46: 139-45.
13. Jones ME, Critchley IA, Karlowsky JA et al. In vitro activities of novel nonfluorinated quinolones PGE 9262932 and PGE 9509924 against clinical isolates of Staphylococcus aureus and Streptococcus pneumoniae with defined mutations in DNA gyrase and topoisomerase IV. Antimicrob Agents Chemother 2002; 46: 1651-7.
14. LaPlante KL, Rybak MJ, Tsuji B et al. Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. Antimicrob Agents Chemother 2007; 51: 1315-20.
15. Li Z, Deguchi T, Yasuda M et al. Alteration in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV in quinolone-resistant clinical isolates of Staphylococcus epidermidis. Antimicrob Agents Chemother 1998; 42: 3293-5.
16. Li X, Mariano N, Rahal JJ et al. Quinolone-resistant Haemophilus influenzae in a long-term-care facility: nucleotide sequence characterization of alterations in the genes encoding DNA gyrase and DNA topoisomerase IV. Antimicrob Agents Chemother 2004; 48: 3570-2.
17. Perez-Vazquez M, Roman F, Aracil B et al. Laboratory detection of Haemophilus influenzae with decreased susceptibility to nalidixic acid, ciprofloxacin, levofloxacin, and moxifloxacin due to GyrA and ParC mutations. J Clin Microbiol 2004; 42: 1185-91.
18. Yamada M, Yoshida J, Hatou S et al. Mutations in the quinolone resistance determining region in Staphylococcus epidermidis recovered from conjunctiva and their association with susceptibility to various fluoroquinolones. Br J Ophthalmol 2008; 92: 848-51.
19. Cambau E, Matrat S, Pan XS et al. Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli. J Antimicrob Chemother 2009; 63: 443-50.
20. Proksch JW, Granvil CP, Mermet-Siou R et al. Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans. J Ocul Pharmacol Ther 2009; 25: 335-44.
21. Ward KW, Lepage JF, Driot JY. Nonclinical pharmacodynamics, pharmacokinetics, and safety of BOL-303224-A, a novel fluoroquinolone antimicrobial agent for topical ophthalmic use. J Ocul Pharmacol Ther 2007; 23: 243-56.
22. Karpecki P, DePaolis M, Hunter JA et al. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: a multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study. Clin Ther 2009; 31: 514-26.
23. McDonald MB, Protzko EE, Brunner LS et al. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis. Ophthalmology 2009; 116: 1615-23.
24. Tepedino ME, Heller WH, Usner DW et al. Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. Curr Med Res Opin 2009; 25: 1159-69.
25. Wright DH, Brown GH, Peterson ML et al. Application of fluoroquinolone pharmacodynamics. J Antimicrob Chemother 2000; 46: 669-83.
26. Allen GP, Kaatz GW, Rybak MJ. In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic model. Int J Antimicrob Agents 2004; 24: 150-60.
27. Metzler K, Hansen GM, Hedlin P et al. Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus. Int J Antimicrob Agents 2004; 24: 161-7.